Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1

Lancet

Volumn 357, Issue 9257, 2001, Pages 687-688

  Benn, Paul D ^a,d   Mercey, Danielle E ^b   Brink, Nicola ^b   Scott, Geoffrey ^c   Williams, Ian G ^b  

^a CAMDEN AND ISLINGTON NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; DRUG SAFETY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; PROPHYLAXIS; VIRUS TRANSMISSION;

EID: 0035799102     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04139-8     Document Type: Article

References (5)

1. Case-control study of HIV seroconversion in healthcare workers after percutaneous exposure to HIV-infected blood - France, United Kingdom and United States, January 1988-August 1994
2. Tolerability and side effects of post-exposure prophylaxis for HIV infection
3. Absolute bioavailability of nevirapine in healthy volunteers following oral and intravenous administration